#United States #New Orleans #Cardiologists #NYU Langone Heart #ACC.26

NYU Langone Heart Cardiologists Present Latest Research at ACC.26

NYU Langone Health's cardiologists showcased their latest clinical findings and research at the American College of Cardiology's Annual Scientific Session, ACC.26, held from March 28 to 30, 2026 in New Orleans. This event highlighted various groundbreaking studies, featuring insights into early cardiovascular risk factors, innovative imaging techniques, and tailored treatment strategies for cardiovascular diseases.

Among the prominent topics presented was the Postpartum Heart Program, which revealed that women suffering from high blood pressure during pregnancy may face increased long-term cardiovascular risks. Researchers evaluated a cohort of 132 women approximately three months after delivery, discovering alarming statistics: 40% of the participants were obese, 70% had elevated cholesterol levels, and 25% presented chronic high blood pressure. Surprisingly, among women without a prior history of hypertension, 13% developed it within six months after giving birth.

Dr. Anais Hausvater, co-director of NYU Langone's Cardio-Obstetrics Program, emphasized, “Pregnancy can act as an early warning sign for future heart disease.” This study illustrates the critical period postpartum for assessing cardiovascular health, enabling proactive measures to safeguard long-term heart health.

Another intriguing presentation involved the detection of hidden cardiac amyloidosis in patients undergoing surgery for Hypertrophic Cardiomyopathy (HCM). A study encompassing 565 patients discovered that 1.6% of them had undiagnosed cardiac amyloidosis, despite exhibiting typical HCM symptoms. Dr. Daniele Massera, the senior author of the study, commented on the implications of these findings, stating that cardiac amyloidosis may occur even when not suspected based on standard tests. This underscores the importance of thorough evaluations, especially as targeted treatments for cardiac conditions are becoming more prevalent.

Further, advancements in imaging technology led to discussions on dual imaging techniques that help identify heart attack causes in patients without blocked arteries. These insights can significantly change how cardiologists approach diagnosis and treatment.

The conference also featured a unique barbershop-based program aimed at preventing worsening blood pressure in Black men. Dr. Joseph E. Ravenell shared how combining community engagement with healthcare initiatives can lead to better health outcomes.

Dr. Michelle Bloom, who leads the Cardio-Oncology Program, discussed the concept of “permissive cardiotoxicity”, advocating for the careful management of cancer treatments that may impact heart health. This evolving paradigm highlights the collaboration between oncologists and cardiologists to ensure that cancer patients can continue vital treatments while monitoring and managing cardiovascular side effects.

Additional research on bioprosthetic heart valves revealed concerning patterns among younger patients. Studies indicated that bioprosthetic valves might wear out faster in younger individuals, raising questions about the choice of valve types based on age and specific underlying conditions. Patients identified as “rapid degenerators”, experienced valve failures within five years due to factors like inflammation and autoimmune disorders.

In total, NYU Langone faculty participated in over 60 presentations and discussions across the conference, making significant contributions to the collective knowledge surrounding cardiovascular health. Dr. Glenn I. Fishman, director of the Leon H. Charney Division of Cardiology, noted, “These findings reflect a broader shift towards proactive, customized, and multi-faceted care in cardiology.”

NYU Langone Health continues to be recognized as a leader in cardiovascular care, consistently achieving top rankings in specialized treatment areas, including heart rhythm disorders and congenital heart disease. As research and clinical practices evolve, the institution remains committed to enhancing patient outcomes through quality care and innovation.

For more detailed insights into the presented studies or other inquiries, connect with NYU Langone Health representatives.